UPDATE 1-U.S. FDA panel favors new safety information on AstraZeneca's Onglyza
April 14, 2015 at 13:11 PM EDT
WASHINGTON, April 14 (Reuters) - AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday.
